Maplight Therapeutics (NASDAQ:MPLT) Insider Erin Pennock Foff Sells 24,052 Shares of Stock
by Jessica Moore · The Cerbat GemMaplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report) insider Erin Pennock Foff sold 24,052 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $28.76, for a total transaction of $691,735.52. Following the sale, the insider directly owned 350,497 shares in the company, valued at approximately $10,080,293.72. The trade was a 6.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Erin Pennock Foff also recently made the following trade(s):
- On Tuesday, May 5th, Erin Pennock Foff sold 10,576 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.20, for a total transaction of $298,243.20.
- On Monday, May 4th, Erin Pennock Foff sold 15,652 shares of Maplight Therapeutics stock. The stock was sold at an average price of $27.96, for a total transaction of $437,629.92.
Maplight Therapeutics Trading Up 4.0%
MPLT stock opened at $29.04 on Thursday. Maplight Therapeutics, Inc. has a twelve month low of $12.24 and a twelve month high of $33.28. The business’s 50 day moving average is $22.60. The firm has a market capitalization of $1.24 billion and a PE ratio of -0.73.
Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last released its quarterly earnings data on Thursday, March 26th. The company reported ($2.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). On average, equities analysts predict that Maplight Therapeutics, Inc. will post -3.96 EPS for the current year.
Hedge Funds Weigh In On Maplight Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Fcpm Iii Services B.V. purchased a new position in Maplight Therapeutics in the 4th quarter valued at $56,672,000. T. Rowe Price Investment Management Inc. purchased a new position in Maplight Therapeutics in the 4th quarter valued at $49,154,000. Goldman Sachs Group Inc. purchased a new position in Maplight Therapeutics in the 4th quarter valued at $34,026,000. Nan Fung Group Holdings Ltd purchased a new position in Maplight Therapeutics in the 4th quarter valued at $17,060,000. Finally, 5AM Venture Management LLC purchased a new position in Maplight Therapeutics in the 4th quarter valued at $16,687,000.
Trending Headlines about Maplight Therapeutics
Here are the key news stories impacting Maplight Therapeutics this week:
- Positive Sentiment: HC Wainwright opened/updated coverage and issued detailed quarterly and FY estimates alongside a Buy rating and a $45 price target (implies ~55% upside from the recent price); the report provides a near‑term analyst catalyst and a bullish valuation anchor. HC Wainwright coverage (MarketBeat)
- Positive Sentiment: Needham reaffirmed its Buy rating on MPLT, reinforcing sell‑side support that can sustain buying interest. Needham reaffirmation (The Globe and Mail)
- Neutral Sentiment: Morningstar quote/coverage appears in the tape (useful for tracking consensus/third‑party data) but contains no new fundamental update by itself. Morningstar MPLT quote
- Negative Sentiment: Significant insider selling reported May 4–6: CEO Christopher Kroeger sold multiple blocks (~23,701 shares on May 6 and earlier sales), CFO Vishwas Setia, and insiders James W. Lillie and Erin P. Foff also sold material stakes. These transactions reduce insider holdings and may add near‑term supply pressure, though each sale was made under pre‑arranged Rule 10b5‑1 plans (which weakens the signal that sales reflect new negative company information). See CEO Form 4 filing. CEO Form 4 (SEC)
- Negative Sentiment: Additional insider Form 4 filings for James W. Lillie and Erin P. Foff confirm multi‑day sales at similar prices (May 4–6). Investors should monitor total sold vs. remaining insider ownership and trading volume to gauge impact. James W. Lillie Form 4 (SEC)
Wall Street Analyst Weigh In
A number of research firms have weighed in on MPLT. TD Cowen initiated coverage on shares of Maplight Therapeutics in a report on Tuesday, April 7th. They set a “buy” rating on the stock. Wall Street Zen lowered shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Canaccord Genuity Group initiated coverage on shares of Maplight Therapeutics in a research report on Thursday, March 19th. They set a “buy” rating and a $35.00 target price on the stock. Weiss Ratings initiated coverage on shares of Maplight Therapeutics in a research report on Thursday, January 22nd. They set a “sell (e)” rating on the stock. Finally, Needham & Company LLC initiated coverage on shares of Maplight Therapeutics in a research report on Wednesday, April 8th. They set a “buy” rating and a $37.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Maplight Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.43.
Check Out Our Latest Research Report on Maplight Therapeutics
About Maplight Therapeutics
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.